Blockade of tachykinin NK 1/NK 2 receptors in the brain attenuates the activation of corticotrophin-releasing hormone neurones in the hypothalamic paraventricular nucleus and the sympathoadrenal and pituitary-adrenal responses to formalin-induced pain in the rat

Journal of Neuroendocrinology

Volumn 22, Issue 5, 2010, Pages 467-476

  Culman, J ^a   Das, G ^c   Ohlendorf, C ^a   Haass, M ^b   Maser Gluth, C ^b   Zuhayra, M ^a   Zhao, Y ^a   Itoi, K ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

ACTH; Catecholamines; CRH; Pain; Paraventricular nucleus; Rat; Substance P

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; ADRENALIN; CATECHOLAMINE; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; FORMALDEHYDE; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; OXYTOCIN; PROTEIN C FOS; SAREDUTANT; SUBSTANCE P; TACHYKININ; VASOPRESSIN; TACHYKININ RECEPTOR;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR RESPONSE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; HEART RATE; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MEAN ARTERIAL PRESSURE; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; STIMULUS RESPONSE; STRESS; SUPRAOPTIC NUCLEUS; ANIMAL; ANTERIOR HYPOTHALAMUS; BLOOD PRESSURE; BRAIN; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; HYPOPHYSIS ADRENAL SYSTEM; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; BRAIN; CORTICOTROPIN-RELEASING HORMONE; FORMALDEHYDE; HEART RATE; NEURONS; PAIN; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; RATS; RECEPTORS, TACHYKININ;

EID: 77957348350     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2010.01987.x     Document Type: Article

References (42)

1. Page NM. Hemokinins and endokinins. Cell Mol Life Sci 2004; 61: 1652-1663.
2. Regoli D, Boudon A, Fauchére J-L. Receptors and antagonists for subastance P an related peptides. Pharmacol Rev 1994; 46: 551-599.
3. Pennenfather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA.Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74: 1445-1463.
4. Unger T, Carolus S, Demmert G, Ganten D, Lang RE, Maser-Gluth C, Steinberg H, Veelken R. Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization. Circ Res 1988; 63: 812-820.
5. Womack MD, Morris R, Gent TC, Barrett-Jolley R. Substance P targets sympathetic control neurons in the paraventricular nuclues. Circ Res 2007; 100: 1650-1658.
6. Ebner K,Singewald N. Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 73-82.
7. Singewald N, Chicchi GG, Thurner CC, Tsao K-L, Spetea M, Schmidhammer H, Sreepathi HK, Ferraguti F, Singewald GM, Ebner K. Modulation of basal and stress- induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J Neurochem 2008;106: 2476-2488.
8. Culman J, Klee S, Ohlendorf C, Unger T. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J Pharmacol Exp Ther 1997; 280: 238-246.
9. Chowdrey HS, Jessop DS, Lightman SL. Substance P stimulates arginine vasopressin and inhibits adrenocorticotropin release in vivo in the rat.Neuroendocrinology 1990; 52: 90-93.
10. Faria M, Navarra P, Tsagarakis S, Besser GM, Grossman AB. Inhibition of CRH-41 release by substance P, but not substance K, from the rat hypothalamus in vitro. Brain Res 1991; 538: 76-78.
11. Jessop DS. Central non-glucocorticoid inhibitors of the hypothalamopituitary-adrenal axis. J Endocrinol 1999; 160: 169-180.
12. Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids 2006; 31: 251-272.
13. Ebner K, Sartori SB, Singewald N. Tachykinin receptors as targets in stress related Disorders. Curr Pharm Des 2008; 15: 1647-1674.
14. Culman J, Ritter S, Ohlendorf C, Haass M, Maser-Gluth C, Spitznagel H,Unger T. A new formalin test allowing simultaneous evaluation of cardiovascular and nociceptive responses. Can J Physiol Pharmacol 1997;75: 1203-1211.
15. Baulmann J, Spitznagel H, Herdegen T, Unger T, Culman J. Tachykinin receptor inhibition and c-Fos expression in the rat brain following formalin-induced pain. Neuroscience 2000; 95: 813-820.
16. Culman J, Kopin IJ, Saavedra JM. Regulation of corticotropin-releasing hormone and pituitary-adrenocortical response during acute and repeated stress in the rat. Endocr Regul 1991; 25: 151-158.
17. Rupniak NMJ, Boyce S, Williams AR, Cook G, Longmore J, Seabrook GR,Caeser M, Iversen SD, Hill RG. Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580. Br J Pharmacol 1993; 110: 1607-1613.
18. Martin CA, Emonds-Alt X, Advenier C. Inhibition of cholinergic neurotransmission in isolated guinea-pig main bronchi by SR 48968. Eur J Pharmacol 1993; 243: 309-312.
19. 2 binding sites in the rat brain. J Neurochem 2001; 79: 985-996.
20. 3 binding sites. Neuroscience 2003; 116: 761-773.
21. de Lange RPJ, Wiegant VM, Stam R. Altered neuropeptide Y and neurokinin messenger RNA expression and receptor binding in stresssensitised rats. Brain Res 2008; 1212: 35-47.
22. Picard P, Regoli D, Couture R. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists. Br J Pharmacol 1994; 112: 240-249.
23. Itoi K, Jost N, Culman J, Tschöpe C, Unger T. Further localization of cardiovascular and behavioral actions of substance P in the rat brain. Brain Res 1994; 668: 100-106.
24. Bittencourt JC, Benoit R, Sawchenko PE. Distribution and origins of substance P-immunoreactive projections to the paraventricular and supraoptic nuclei: partial overlap with ascending catecholaminergic projections. J Chem Neuroanat 1991; 4: 63-78.
25. Buck SH, Helke CJ, Burcher E, Shults CW, O'donohue TL. Pharmacologic characterization and autoradiographic distribution of binding sites for iodinated tachykinins in the rat central nervous system. Peptides 1986;7: 1109-1120.
26. Strack AM, Sawyer WB, Platt KB, Loewy AD. CNS group regulating the sympathetic outflow to adrenal gland as revealed by transneuronal cell body labeling with pseudorabies virus. Brain Res 1989; 491:274-296.
27. Brown M, Fisher L, Webb V, Vale WW, Rivier JE. Corticotropin-releasing factor: a physiologic regulator of adrenal epinephrine secretion. Brain Res 1985; 328: 355-357.
28. Grosskreutz CL, Brody MJ. Regional hemodynamic responses to central administration of corticotropin-releasing factor (CRF). Brain Res 1988;442: 363-367.
29. Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 1999; 46: 1167-1180.
30. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Donat F, Poncelet M, Gueudet C, Desvignes C, Le Furg, Soubrié P. Selective blockade of nerokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001; 299: 449-458.
31. Louis C, Stemmelin J, Boulay D, Bergis O, Cohen C, Griebel G. Additional evidence for anxiolytic-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models. Pharmacol Biochem Behav 2008; 89: 36-45.
32. Kakol-Palm D, Brusberg M, Sand E, Larsson H, Martinez V, Johansson A,von MentzerBPåhlmanI, Lindström E. Role of tachykinin NK1 and NK2 receptors in colonic sensitivity and stress-induced defecation in gerbils.Eur J Pharmacol 2008; 582: 123-131.
33. 1). J Clin Psychiatry 2002; 63(Suppl 11): 11-17.
34. de SousaMello DM, Marcinichen DR, Madruga D, Branco R, Paschoalini MA, Monteiro deLima TC. Involvement of NK1 receptrors in metabolic stress markers after central administration of substance P. Behav Brain Res 2007; 181: 232-238.
35. Spitznagel H, Baulmann J, Blume A, Unger T, Culman J. C-Fos expression in the rat brain in response to substance P and neurokinin B. Brain Res 2001; 916: 11-21.
36. Miklo's IH, Kova'cs KJ. Gabaergic innervation of corticotropin-releasing hormone (CRH)- secreting parvocellular neurons and its plasticity as demonstrated by qualitative immunoelectron microscopy. Neuroscience 2002; 113: 581-592.
37. Hwang BH,Katner J, Iyengar S. Corticotropin-releasing factor mRNA and substance P receptor binding in the paraventricular hypothalamic nucleus, central nucleus of the amygdala, and locus coeruleus of Sprague-Dawley rats following restraint-induced stress. J Mol Neurosci 2005;25: 239-250.
38. Pacák K, Palkovits M. Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. Endocr Rev 2001;22: 502-548.
39. Palkovits M, Baffi JS, Pacak K. The role of ascending neuronal pathways in stress-induced release of noradrenaline in the hypothalamic paraventricular nucleus of rats. J Neuroendocrinol 1999; 11: 529-539.
40. Itoi K, Suda T, Tozawa F, Dobashi I, Ohmori N, Sakai Y, Abe K, Demura H.Microinjection of norepinephrine into the paraventricular nucleus of the hypothalamus stimulates corticotropin-releasing factor gene expression in conscious rats. Endocrinology 1994; 135: 2177-2182.
41. Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 2009; 18: 1843-1864.
42. Chahl LA. Tachykinins and neuropsychaitric disorders. Curr Drug Targets 2006; 7: 993-1003.